SEC Form 4 · accession 0001140361-17-027380
RESMED INC · RMD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Peter C Farrell
Director
Period of report
Jul 5, 2017
Accepted (ET)
Jul 6, 2017 · 6:13 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000943819
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| ResMed Common Stock | Jul 5, 2017 | M | 20,000 | $27.58 | A | 321,557 | D | |
| ResMed Common StockF2 | Jul 5, 2017 | S | 19,600 | $76.49 | D | 301,957 | D | |
| ResMed Common StockF3 | Jul 5, 2017 | S | 400 | $77.15 | D | 301,557 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Resmed Stock Option PlanF4 | $27.58 | Jul 5, 2017 | M | 20,000 | D | Nov 11, 2012 | Nov 16, 2018 | ResMed Common Stock | 20,000 | 162,460 | D |
Explanation of responses
- F1The transaction was conducted under a Rule 10b5-1 plan.
- F2This transaction was executed in multiple trades at prices ranging from 75.83 to 76.76. The price reported above represents the weighted average sales price.
- F3This transaction was executed in multiple trades at prices ranging from 76.83 to 77.26. The price reported above represents the weighted average sales price.
- F4Represents date options first became exercisable. Options vested 1/4 per year.